Epithelial ovarian cancer is the most lethal gynaecological malignancy and the fifth leading cause of cancer-related death in women in western countries. Due to lack of specific symptoms and effective screening methods, the majority of cases are diagnosed at advanced stages. Since survival probability drops significantly with increasing stage, epithelial ovarian carcinoma (EOC) patients in general face a poor prognosis, with an estimated 5-year survival rate of around 27% ([@bib34]).

Epithelial ovarian cancer is a very heterogeneous disease that can be stratified using different criteria. Based on molecular and developmental features, EOCs can be divided into type I and type II tumours. Type I tumours arise in a progressive manner from benign, through borderline to low-malignant potential neoplasm. Type II tumours grow rapidly without well-defined premalignant lesions and are typically diagnosed as high-grade serous, high-grade endometroid, or undifferentiated carcinomas depending on the dominant pattern ([@bib23]). Tumours can also be classified as hereditary or sporadic when they arise in patients with or without a family history of the disease, respectively. Overall, around 10--15% of invasive EOCs are estimated to involve hereditary susceptibility ([@bib2]). The majority of these cases are explained by germline mutations in the *BRCA1* or *BRCA2* tumour suppressor genes ([@bib2]; [@bib30]) although additional genes such as *BRIP1*, *RAD51C* and *RAD51D* have been recently shown to confer ovarian cancer susceptibility ([@bib30]). Clinical and histopathological differences between *BRCA1*- and *BRCA2*-related tumours and those arising in non-mutation carriers have been reported ([@bib36]). Importantly, germline *BRCA1/2* mutations have been associated with improved survival and chemotherapy response ([@bib1]; [@bib5]; [@bib30]).

It has been suggested that hereditary and sporadic EOCs might evolve in distinct ways, especially due to early homologous recombination (HR) impairment in carriers of *BRCA1* or *BRCA2* mutations ([@bib29]; [@bib16]; [@bib43]). However, it is still unclear exactly which mechanisms are involved in cancer development in *BRCA1/2* mutation carriers, and whether they differ from those taking place in sporadic cases. One way to get insight into this issue is to compare the rate and pattern of DNA copy number changes exhibited by these tumour types. This approach is particularly relevant in a view of the results from the recently published Cancer Genome Atlas (TCGA) study ([@bib38]). This the most comprehensive analysis of high-grade EOCs carried out so far revealed that these tumours present a relatively simple mutational spectrum, but are characterised by a large degree of genome instability.

So far few studies have specifically analysed the DNA copy number changes that characterise the different groups of hereditary ovarian tumours (*BRCA1, BRCA2* and those from non-*BRCA1/2*-mutation carriers, also called 'BRCAX\') or have compared these changes with those observed in sporadic neoplasms ([@bib29]; [@bib46]; [@bib16]; [@bib33]; [@bib24]). Moreover, the few studies conducted have yielded contradictory results, which might be due to the limited number of tumours included ([@bib29]; [@bib16]; [@bib24]), the use of low-resolution techniques ([@bib29]; [@bib33]) or the application of different algorithms. Interestingly, the TCGA ovarian study reported that tumours with *BRCA1/2* alterations do not exhibit increased genomic instability compared with wild-type tumours ([@bib38]). However, that comparison was only made of the total level of DNA copy number alterations with no distinction between gained or lost events. In addition, the TCGA ([@bib38]) and other studies ([@bib22]) jointly describe the DNA copy number alterations that occur in tumours carrying germline, somatic and/or epigenetic inactivation of the *BRCA1* or *BRCA2* genes. Nevertheless, it is still not clear whether the mechanisms by which these genes are rendered non-functional might be relevant to the natural history of the tumours and to the changes that arise and are selected throughout the oncogenic process.

Our study addresses some of these limitations by using a homogeneous series of ovarian tumours from patients of well-characterised high-risk breast and ovarian cancer families. Moreover, this series includes not only cases from carriers of germline *BRCA1/2* mutations, but also from hereditary BRCAX cases. In addition, we use high-resolution array Comparative Genomic Hybridisation (aCGH) and pay special attention to the separate analysis of gain and loss events. This approach, although still limited, allowed us to obtain further insight into this poorly explored field and to define potential differences and similarities in genomic instability between these tumour groups.

Materials and methods
=====================

Additional information can be found in [Supplementary Methods](#sup1){ref-type="supplementary-material"}.

Patients and tumours
--------------------

At total of 72 formalin-fixed paraffin-embedded (FFPE) epithelial ovarian tumours were analysed. Fifty seven corresponded to patients from high-risk breast and ovarian cancer families and fifteen to sporadic patients. Families selected for this study fulfilled one of the following criteria: (a) at least two cases of ovarian cancer in the same family line; (b) at least one case of ovarian cancer and at least one case of breast cancer in the same family line; (c) at least one woman with both breast and ovarian cancer; (d) at least one woman with bilateral ovarian cancer. Mutation testing of *BRCA1* and *BRCA2* genes was carried out using previously described methods ([@bib28]). In total, paraffin blocks from 21 *BRCA1*, 6 *BRCA2* and 30 BRCAX tumours were obtained from different hospitals throughout Spain. Sporadic cases (with no reported first or second degree relative with breast or ovarian cancer), used for comparison purposes, were obtained from a single institution (Hospital Virgen del Rocio, Seville) and were selected to match the distribution of histological subtypes in familial series.

All tumours were blindly reviewed by two pathologists (IMR and JP) and classified histopathologically. Immunohistochemical expression of markers such as Wilms Tumour protein (WT1), tumour protein p53 (TP53), oestrogen receptor (ESR), progesterone receptor (PGR) and cyclin-dependent kinase inhibitor 2A (p16) (CDKN2A) was performed to assist in the differential diagnosis ([@bib21]; [@bib20]). Grading of serous tumours was performed according to two-tier MD Anderson Cancer Center (MDACC) system ([@bib25]; [@bib13]) while the rest of the histological types was graded according to World Health Organisation criteria ([@bib35]; [@bib45]). A subgroup of tumours within the type II carcinomas was defined to allow for comparisons between more homogenous groups of high-grade neoplasms. This subgroup consisted of high-grade serous tumours of solid growth pattern and undifferentiated carcinomas (hereafter referred as to 'subgroup of type II tumours\'). Detailed information is shown in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}. The study was approved by the research ethics committees from each of the participating centres and all patients gave informed consent.

DNA isolation and labelling
---------------------------

Genomic DNA was extracted from three 10-μm-thick FFPE tissue sections per tumour. After deparaffination and rehydration, sections were hematoxylin and eosin (H&E) stained and tumour areas were delimited by a pathologist and macrodissected with a surgical blade to ensure at least 80% tumour content. DNA extraction was carried according to standard protocol including overnight proteinase K digestion and using QIAamp DNA mini kit (Qiagen, Westburg, Leusden, The Netherlands) according to manufacturer\'s instructions. Labelling of test and reference DNA was performed with the Enzo Genomic DNA labeling kit (Enzo Life Sciences, Farmingdale, NY, USA) as described previously. In 45 out of 72 hybridisations (62%), patient-matched normal DNA was used as a reference (in 26 from conserved normal tissue and in 19 from the patient\'s peripheral blood). In the remaining 27 hybridizations (38%), a pool of normal DNA from healthy females was used as a reference (<http://www.kreatech.com/products/megapool-reference-dna.html>).

Hybridisations, scanning and image acquisition
----------------------------------------------

Hybridisations were performed on slides of four arrays, each containing 180 880 *in situ* synthesised 60-mer oligonucleotides (4 × 180 K, Agilent Technologies, Palo Alto, CA, USA) representing 169 793 unique chromosomal locations evenly distributed across the genome (space∼17 kb), and 4548 additional unique oligonucleotides, located at 238 of the Cancer Census genes (<http://www.sanger.ac.uk/genetics/CGP/Census/>). Oligonucleotide positions were defined according to the NCBI36/hg18 assembly (March 2006). Hybridisation, scanning and feature extraction were carried out as previously described ([@bib7]). The aCGH data have been deposited in NCBI\'s Gene Expression Omnibus ([@bib11]) and are accessible through GEO accession number GSE41253 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41253>).

Preprocessing and processing
----------------------------

Data normalisation, segmentation and calling were performed in R (v.2.8.2 and 2.13; <http://www.r-project.org>), using median normalisation and Wave Smoothing and CGH-call packages ([@bib40]). For visualisation and downstream processing, data were analysed in Nexus Copy Number v5.1 (BioDiscovery, Inc., El Segundo, CA, USA). The WECCA (Weighted Clustering of Called aCGH Data) R package ([@bib41]) was used for unsupervised hierarchical clustering (total linkage and overall similarity algorithms).

Degree of genomic instability: number and length of alterations
---------------------------------------------------------------

To determine the degree of genomic instability in each subgroup of tumours (BRCA1/2/X and sporadic), total number of alterations and of a particular type (homozygous deletions (HDs)/losses/gains/amplifications) were calculated per sample. Total size of altered genome and size accounted for by gains and losses was calculated by adding up the lengths of individual segments. Next, average number of changes and average size of altered genome were calculated for sporadic tumours and for each group of familial tumours. To determine the relative contribution of each type of change (losses or gains), the ratio of the average number of losses to the average number of gains within each tumour subtype was computed. Similarly, the ratio of the average length of the lost genome to the average length of gained was calculated.

Common and potentially specific regions of copy number changes
--------------------------------------------------------------

To visualise the general pattern of chromosomal changes, frequency plots and a list of recurrent minimal common regions (MCRs) of alterations were generated for each tumour subtype (BRCA1/2/X and sporadic) using Nexus Copy Number v5.1 (BioDiscovery, Inc.). Potentially group-specific alterations were defined using Fisher\'s Exact Test (FET) (*P*-value\<0.05) implemented in Nexus and chi-square test within CGHtest (R package) with correction for multiple testing (FDR\<0.02).

The list of potentially group-specific regions was further refined using data from the TCGA ovarian study ([@bib38]) as described in [Supplementary Materials](#sup1){ref-type="supplementary-material"}.

Immunohistochemical analysis
----------------------------

To validate our hybridisation and analytical approaches, we selected three high-amplitude events (HDs at the *CDKN2A* and *RB1* loci and amplification at the *CCNE1* locus) to determine the consistency between the assigned DNA copy number status and the expression levels of the target proteins. Details are explained in [Supplementary Materials](#sup1){ref-type="supplementary-material"} and shown in [Supplementary Table S2](#sup1){ref-type="supplementary-material"}.

Statistical analyses
--------------------

Statistical analyses were performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA). Comparison of continuous variables (number and size of alterations between different tumour groups and clusters) was done using Student\'s two-tailed *t*-test (for variables of normal distribution) or the Mann--Whitney test (non-parametric distributions). For categorical data (FIGO stage, *BRCA1/2* mutation status, etc.), chi-square or Fisher\'s Exact Test were applied, depending on the size of the compared groups.

Results
=======

Tumour characteristics
----------------------

In our series of 57 familial tumours, 4 were classified as borderline lesions and 53 corresponded to carcinomas. The borderline tumours were analysed separately (data not shown) and excluded from this study. All of them belonged to the BRCAX group. Most tumours from *BRCA1/2* mutation carriers were serous, high grade and high FIGO stage. In contrast, BRCAX tumours were more heterogeneous and presented a wider range of histological subtypes and stages. As expected, hereditary patients were diagnosed at a significantly younger age than sporadic ones (51 *vs* 62 years, *P*=0.001). Patient and tumour characteristics are summarised in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

Number and length of copy number alteration across tumour subtypes
------------------------------------------------------------------

Overall, the pattern of copy number alterations was not substantially different between familial (all subtypes) and sporadic tumours ([Figure 1A](#fig1){ref-type="fig"}). Likewise, there were no significant differences between familial and sporadic tumours regarding the average total number of alterations and the average total length of genome altered per tumour (considering all carcinomas and the subgroup of type II neoplasms, the latter defined as described in Materials and methods) ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Both familial and sporadic tumours were characterised by a high level of genomic instability, which in the subgroup of type II carcinomas was exemplified by an average of \>60 aberrations per tumour that involved \>1 Mb of the genome ([Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Despite this general similarity, a separate analysis of gains and losses and stratification of familial tumours according to their *BRCA1/2* mutation status revealed some differences.

*BRCA1* and *BRCA2* tumours presented a greater average number of losses and HDs than sporadic or BRCAX tumours, while sporadic cases presented the highest average number of gains and amplifications of all tumour subtypes ([Figure 2A](#fig2){ref-type="fig"}; [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). A similar pattern was observed when only high-grade tumours were considered ([Figure 2B](#fig2){ref-type="fig"}; [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Comparisons of gains and losses within each tumour subtype revealed that sporadic tumours presented a similar average number of both events (25.7 *vs* 25.6, respectively). However, in familial tumours the average number of losses was 1.4 times greater than the average number of gains, with differences mostly attributed to *BRCA1* (29.6 losses *vs* 21.7 gains, *P*=0.02) and *BRCA2* tumours (32.7 losses *vs* 14.5 gains, *P*=0.009) ([Figure 2C](#fig2){ref-type="fig"}; [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). This was also observed in the subgroup of type II tumours, with significant and borderline significant differences between numbers of gains and losses in *BRCA2* and *BRCA1* tumours, respectively ([Figure 2D](#fig2){ref-type="fig"}; [Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

In agreement with the analysis of the number of alterations, we found that *BRCA1* and *BRCA2* tumours presented a significantly higher average length of genome altered due to losses than sporadic or BRCAX tumours ([Figure 2E](#fig2){ref-type="fig"}; [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). This pattern was partially maintained in the subgroup of type II carcinomas, with significant differences between tumours from BRCA2 and BRCAX patients ([Figure 2F](#fig2){ref-type="fig"}; [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Interestingly, in all tumour subtypes, including the sporadic group, which showed similar average numbers of both alterations, more genetic material was lost than gained ([Figures 2G and H](#fig2){ref-type="fig"}; [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). In *BRCA1* and *BRCA2* tumours, the average length of lost genome was 2.1 and 3.8-fold greater than the length of gained material, respectively. In sporadic and BRCAX tumours, differences were less marked (1.6-fold in both) ([Figure 2G](#fig2){ref-type="fig"}; [Supplementary Table S3](#sup1){ref-type="supplementary-material"}). Differences between length of genome gained and lost per tumour were statistically significant in all familial tumours (*BRCA1*, *BRCA2* and BRCAX), while only a trend was observed in sporadic cases (*P*=0.09). In the subgroup of type II tumours, only differences in BRCA1/2 carriers remained significant (*P*\<0.001) ([Figure 2H](#fig2){ref-type="fig"}; [Supplementary Table S3](#sup1){ref-type="supplementary-material"}).

Common and group-specific copy number alterations
-------------------------------------------------

A summary of common gains and losses identified as recurrent in at least three of the analysed tumour subtypes (*BRCA1*, *BRCA2*, BRCAX and sporadic) is shown in [Table 1](#tbl1){ref-type="table"}. Regions recurrently gained in the four tumour subtypes were 6p25.3, 8q24.2-q24.3 and 12p13.33-p13.32, and regions exhibiting the highest frequencies were 3q26.2 and 8q24.2-q24.3 ([Figure 1A--I](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). These regions and others defined as recurrently gained included from 1 up to 45 genes and spanned well-known or potential oncogenes such as *MECOM, PIK3CA*, *FOXQ1, MYC, CCND2* and *CANT1.* Regions recurrently lost in all four subgroups were defined at 9p24.3, 9p21.3, 17q11.2-q12, 22q12.3, 22q13.1 and 22q13.31-q13.33. Alterations of the highest incidence were found at 8p23.3-p23.1 and 17p13.3-p11.2 ([Figure 1A--I](#fig1){ref-type="fig"}; [Table 1](#tbl1){ref-type="table"}). Many of these deleted regions and the others qualifying as recurrent across tumour subtypes encompassed tumour suppressors previously linked to ovarian carcinogenesis (e.g., *MCPH1, CDKN2A, CDKN2B* and *NF1*). However, other regions pointed to less well-characterised suppressors not previously associated with ovarian cancer (e.g., *FANCC*, *TSC1*, *CREBBP*, *CDH11* and *EDA2R*).

Despite the similar profile of copy number changes exhibited by hereditary and sporadic tumours, supervised analysis unveiled some regions potentially associated with particular tumour subtypes (FDR\<0.2) ([Figure 1A](#fig1){ref-type="fig"}; [Supplementary Table S4](#sup1){ref-type="supplementary-material"}). Among the alterations more recurrently found in *BRCA1* tumours compared with sporadic cases were losses at 4q32.3-q34.1, 6q22.33-q26 or 12q21.2-q23.2 ([Figure 1A and IV](#fig1){ref-type="fig"}) while gains at 6p12-p11, 10p14-p11 and 10q22 were found to be more frequent in BRCAX tumours (compared with *BRCA1* cases; [Figure 1A and IV](#fig1){ref-type="fig"}). Gains at 2p23.3, 12p11.22-p11.1 and 19q12-q13.11 were identified more recurrently in sporadic cases ([Figure 1A and II](#fig1){ref-type="fig"}), with the latter containing the *CCNE1* gene that was also amplified in these tumours.

High level amplifications and HDs
---------------------------------

The high resolution of our platform allowed us to identify focal high-amplitude copy number changes. Fifty-nine narrow amplifications (median length of 739 Kb spanning on average 11 genes) were identified in at least two cases ([Supplementary Table S5](#sup1){ref-type="supplementary-material"}, part A). For instance amplification at 8q22.1, found only in *BRCA1* tumours, presented a MCR that spanned just one gene, the cancer-associated *LAPTM4B*. The most frequent regions of amplification with their distributions across the groups of tumours are shown in [Table 2](#tbl2){ref-type="table"}. In addition, 57 focal HDs (median length of 465 Kbp spanning 6 genes on average) were identified in at least 2 samples ([Table 2](#tbl2){ref-type="table"}; [Supplementary Table S5](#sup1){ref-type="supplementary-material"}, part B). The two most common HDs (9% each) present in all tumour groups were found at 17q11.2 and 13q14.2; each deletion encompassed only one gene (*NF1* and *RB1*, respectively). Other frequent HDs common for sporadic and familial tumours were defined at 8p23.2-p23.1, spanning the early DNA damage-response gene *MCPH1*, and at the fragile site on chromosome 3 (3p14.2) containing the known tumour suppressor *FHIT.*

Immunohistochemical validation of aCGH results
----------------------------------------------

To validate our aCGH results, we assessed the correlation between the assigned DNA copy number and the immunohistochemical expression of three genes targeted by high-amplitude events: *CDKN2A* and *RB1* located at homozygously deleted regions, and *CCNE1* that was found amplified. Immunohistochemical analysis showed complete lack or much lower expression of *CDKN2A* and *RB1* in tumours with HD at these loci compared with the mean value of samples with a flat profile at 9p21.3 and 13q14.2, respectively ([Supplementary Figure S1A and B](#sup1){ref-type="supplementary-material"}). Tumours exhibiting *CCNE1* amplification presented much higher expression compared with the mean value of tumours with normal DNA copy number at this locus ([Supplementary Figure S1C](#sup1){ref-type="supplementary-material"}).

Unsupervised analysis
---------------------

In addition to systematic comparison of copy number alterations across different tumour subtypes, we also carried out unsupervised analysis of the aCGH data to unveil possible associations between particular patterns of genomic changes and the sporadic or familial status of tumours (or hereditary subtype, BRCA1/2/X). Unsupervised hierarchical clustering stratified ovarian carcinomas (*n*=68), based on their copy number changes, into two main clusters (A and B) ([Figure 1B](#fig1){ref-type="fig"}, left panel). Significant differences were not found between tumours from both clusters (or from smaller subgroups) either according to their general familial or sporadic condition or according to their specific BRCA mutation status. In contrast, clustering was associated with genomic instability level, FIGO stage and histological subtype. The cluster with more genomically instable tumours (cluster B) was significantly enriched in high FIGO stage (*P*=0.03) and serous type carcinomas (*vs* all other subtypes, *P*=0.001). Unsupervised hierarchical clustering of the subgroup of type II tumours (*n*=31) also rendered two clusters (II-A and II-B) without significant enrichment in tumours from particular BRCA subgroups ([Figure 1B](#fig1){ref-type="fig"}, right panel).

Discussion
==========

Few studies have addressed the characterisation of DNA copy number changes arising in hereditary ovarian tumours, especially in comparison with more extensively studied familial breast tumours ([@bib15]; [@bib14]; [@bib18]; [@bib26]; [@bib27]; [@bib19]; [@bib37]; [@bib42]; [@bib8]; [@bib12]). The few existing studies have rendered contradictory results, either supporting that mutations in *BRCA1/2* affect the particular chromosomal alterations occurring throughout cancer progression ([@bib33], [@bib32]), or reporting very few copy number changes specifically associated to tumours harbouring such mutations ([@bib16]; [@bib38]). Given these antecedents, the recently confirmed relevance of copy number changes as drivers of ovarian oncogenesis ([@bib38]) and the growing clinical implications of the *BRCA1/2* mutation status, we aimed to determine how hereditary and sporadic ovarian tumours relate to genomic instability and to define common and/or distinct events occurring in the genesis and evolution of these neoplasms. Different from most prior studies, we analysed tumours not only from carriers of *BRCA1/2* mutations, but also from non-*BRCA1/2* hereditary patients (BRCAX tumours) as these have been particularly poorly characterised. Also, we used a high-resolution aCGH platform and separately analysed gains and losses (in contrast to other studies correlating *BRCA1/2* impairment only with global instability).

Our findings indicate lack of substantial differences in the pattern of DNA copy number changes displayed by sporadic carcinomas and the different subtypes of familial tumours. This similarity was illustrated by the existence of shared regions found to be recurrently altered in each individual group of tumours. These common events point to the involvement of genes fundamental for ovarian carcinogenesis, selected throughout the evolution of the tumours and providing advantage to any cancer cell, independently of the existence of germinal mutations in the *BRCA1/2* genes. As possible candidates, we found known players previously related to EOC such as *PIK3CA*, *MECOM*, *MYC*, *NF1* and *RB*, but also less characterised genes, whose gains of function (*CDH12*, *FOXQ1*, *TXNDC5*, *CCND2*, *FOXJ1*) and/or abrogation (*FANCC*, *TSC1*, *CREBBP*, *CDH11, EDA2R*) might be crucial for ovarian cancer development and/or progression. Exploration of the therapeutic opportunities provided by these targets, to which a majority of tumours are likely to be addicted, is an attractive possibility. For instance, it has been suggested that modulation of cellular activities of the forkhead transcription factor *FOXQ1* may have an application in cancer therapy since its inhibition blocks epithelial to mesenchymal transition and results in cancer cell sensitisation to a variety of chemotherapeutic agents ([@bib31]). Therapeutic approaches based on repression of *cyclin D* gene have also been investigated ([@bib39]; [@bib10]) and may be applicable to EOCs presenting aberrant *CCND2* expression due to DNA-copy number gains. Likewise, m-TORC1-directed therapies may be more effective in cancer patients whose tumours present *TSC1* (tuberous sclerosis complex 1) genomic losses as it has been proposed for patients whose tumour harbour *TSC1* somatic mutations ([@bib17]).

Also exemplifying the absence of marked differences in the profile of genomic changes of carriers and non-carriers of *BRCA1/2* mutations, unsupervised hierarchical clustering did not stratify tumours according to their familial or sporadic condition, nor did it according to their *BRCA1/2* mutation status. This is different from what has been reported on familial *BRCA1* and *BRCA2* breast tumours, which show association with particular molecular subtypes (defined with expression arrays) and specific patterns of copy number changes ([@bib18]; [@bib3]; [@bib27]; [@bib37]). Lack of segregation of ovarian tumours from carriers and non-carriers of *BRCA1/2* germline mutations based on their genomic instability pattern would support a model according to which HR repair loss (through inactivation of the *BRCA1/2* genes or other members of the pathway) would not only be a frequent event in high-grade serous ovarian tumours, as recently demonstrated ([@bib38]), but also an event occurring in the initial phases of tumour growth.

Interestingly, despite this general picture of similarity between sporadic and hereditary tumours, differences concerning the overall degree of genomic instability were revealed when gains and losses were analysed separately. Copy number losses were particularly abundant in *BRCA1* and *BRCA2* tumours, both in global terms (comparison of losses made across tumour subtypes) and relative to the number of gains (comparison within each tumour subtype). Although greater contribution of losses than gains was observed in all tumour subtypes, the extent of this phenomenon was more prominent in carriers of *BRCA1* and *BRCA2* mutations. Some prior studies, including the most comprehensive one conducted by the TCGA Research network in high-grade serous ovarian carcinomas, reported no differences in the global degree of instability between tumours with *BRCA1/2* inactivating events and those with functional *BRCA1/2* genes ([@bib38]; [@bib33]). However, no distinction was made between gains and losses, and only comparison of total changes was conducted. Earlier studies already suggested the relevance of loss of heterozygosity (LOH) in ovarian tumours from *BRCA1* and *BRCA2* mutation carriers ([@bib43]; [@bib24]; [@bib44]), but included very few familial cases ([@bib43]; [@bib24]) or used low-resolution platforms ([@bib24]). Our results derived from analysis made across tumour types, within each tumour subgroup and particularly when taking into account only high-grade tumours highlight the relevance of genomic loss in *BRCA1* and *BRCA2* tumours, a phenomenon that would not merely reflect differences related to the higher grade or more prevalent serous histotype of hereditary tumours. Interestingly, correlation between extent of LOH and therapy sensitivity has been recently reported in high-grade serous ovarian tumours ([@bib44]).

Our findings suggest that in the oncogenesis of ovarian tumours, and in particular of hereditary *BRCA1* and *BRCA2* tumours, loss of function of tumour suppressor genes might be under greater selection pressure than gain of function of proto-oncogenes, at least through DNA copy number-related mechanisms. However, lack of clear segregation of *BRCA1* and *BRCA2* tumours in the unsupervised analysis would indicate that most of the genomic loss in carriers does not involve a defined group of critical regions (or specific suppressor genes) recurrently selected during evolution of these particular tumours. Alternatively, greater involvement of loss events in ovarian tumours might be related to impairment of HR function, with grosser effects in *BRCA1* and *BRCA2* tumours due to the central role played by both genes within the pathway.

Although a consistent distinct pattern of copy number changes does not seem to characterise *BRCA1* and *BRCA2* hereditary ovarian tumours, we were able to define several individual regions potentially associated with *BRCA1* tumours (mainly losses) and a few other aberrations (gains and amplifications) potentially associated with sporadic tumours. For instance, losses defined at 4q32.1-q35.2, 13q13.3-q14.3, 17q11.1-q11.2, 17q12, 17q21.32-q21.33, 17q24.3-q25.1 and 22q13.31 found to be related more specifically to *BRCA1* cases in our series, were also previously reported to be associated with this tumour group ([@bib46]; [@bib33]; [@bib9]). The ovarian TCGA study reported only two regions being significantly enriched in one tumour subtype, amplifications at 19p13.13 and 19q12 associated with sporadic tumours (*vs BRCA*-altered tumours). Interestingly, gains and amplifications at 19q12 encompassing *CCNE1* were also defined as potentially associated with sporadic tumours in our analysis. This finding reinforces the proposed role for *CCNE1* and of other proteins implicated in cell-cycle progression as important contributors to ovarian carcinogenesis in tumours with intact BRCA function ([@bib6]; [@bib38]; [@bib4])

In summary, we have performed a comprehensive analysis of the DNA-copy number changes that occur in hereditary EOCs. We have found that overall hereditary and sporadic EOCs exhibit a similar pattern of DNA copy number alterations. However, greater contribution of losses was revealed to be a hallmark of *BRCA1* and *BRCA2* mutation carriers. Importantly, this feature may help to identify BRCA-related patients who have been shown to respond to PARP inhibitors and to present better prognosis when treated with standard regimes.
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![**(**A**) Frequency plots of copy number gains (in green) and losses (in red) defined in all carcinomas and subgroups.** The proportion of tumours with gained/lost regions is plotted on the y axis versus genomic location on the x axis. Common recurrently altered regions across all four subgroups or present in \>55% of the whole series are marked with black arrows on the general plot (for all series), while group-specific regions identified for sporadic, *BRCA1* and BRCAX tumours are identified on the corresponding plots with blue arrows. Simplified chromosomal locations are given next to the arrows (using the same colour code). (**B**) Dendrograms derived from unsupervised hierarchical clustering based on copy number alterations of epithelial ovarian carcinomas (*n*=68) (left panel) and a subgroup of type II carcinomas (*n*=31) (right panel) with colour labels defining the familial or sporadic condition of the tumour as well as the *BRCA* gene mutation status of the sample.](bjc2013141f1){#fig1}

![**Average number (**A**--**D**) and length (**E**--**H**) of copy number alterations in different groups of ovarian carcinomas (**A**, **C**, **E**, **D**) and a subgroup of type II carcinomas (**B**, **D**, **F**, **H**).** Significant differences in number and length of alterations between (**A**, **B**, **E**, **F**) and within (**C**, **D**, **G**, **H**) tumour groups are indicated with \*(*P*\<0.05) or \*\*(*P*\<0.01). Error bars represent 95% Confidence Intervals. ^a^Subgroup of type II carcinomas as defined in Materials and methods.](bjc2013141f2){#fig2}

###### Recurrent minimal common regions (MCRs) of gains and losses shared across tumour subtypes

  **Cytoband**              **Region**                   **Size (bp)**   **Frequency**[a](#t1-fn2){ref-type="fn"} **(%)**   **No. of genes**  **Genes of interest**[b](#t1-fn3){ref-type="fn"}   **Other genes in the region**[c](#t1-fn4){ref-type="fn"}
  ------------------------- --------------------------- --------------- -------------------------------------------------- ------------------ -------------------------------------------------- ----------------------------------------------------------
  **Gains**                                                                                                                                                                                      
  3q26.1                    161 858 336--163 987 311       2 128 975                            37                                 6                                                             *ARL14 PPM1L B3GALNT1 NMD3 C3orf57 OTOL1*
  3q26.2                    170 336 781--170 346 939        10 158                            **56**                               1          ***MECOM***                                         
  3q26.32                   180 277 629--180 352 072        74 443                              54                                 1          ***PIK3CA***                                        
  5p14.3-p14.2              19 297 228--23 809 228         4 512 000                            28                                 5          *CDH18 CDH12 PRDM9*                                *CDH18 GUSBP1 PMCHL1 CDH12 PRDM9*
  **6p25.3**                1 189 126--1 285 230            96 104                              38                                 1          *FOXQ1*                                             
  6p25.1-p24.3              5 776 997--8 041 186           2 264 189                            29                                 16         *NRN1 TXNDC5*                                       
  6p24.1                    13 408 897--13 486 913          78 016                              32                                 2          *TBC1D7*                                           *GFOD1*
  7q32.2-q32.3              129 620 363--130 651 373       1 031 010                            28                                 18                                                             
  7q33-q34                  134 477 470--142 682 704       8 205 234                            30                                 80         *CREB3L2 KIAA1549 **BRAF***                         
  7q35-q36.1                144 378 243--147 685 879       3 307 636                            28                                 3                                                             *CNTNAP2 MIR548F4 MIR548T*
  **8q24.21**               128 807 376--129 291 694        484 318                           **68**                               2          ***MYC***                                          *PVT1*
  **8q24.3**                141 522 457--143 860 659       2 338 202                          **65**                               21         ***TRAPPC9** PSCA*                                  
  10q11.23                  51 473 718--51 664 989          191 271                             31                                 3                                                             *FAM21A FAM21B ASAH2*
  **12p13.33**-**p13.32**   54 933--5 102 331              5 047 398                            37                                 45         ***KDM5A CCND2***                                   
  17q25.1-q25.3             70 225 044--72 286 125         2 061 081                            30                                 26         *FOXJ1*                                             
  17q25.3                   74 387 898--78 774 742         4 386 844                            26                                 93         ***CANT1 ASPSCR1***                                 
  20p13                     0--3 018 638                   3 018 638                            41                                 61         *ANGPT4*                                            
  **Losses**                                                                                                                                                                                     
  4q24                      103 855 981--104 152 060        296 079                             51                                 4                                                             *MANBA UBE2D3 CISD2 NHEDC1*
  4q28.3-q31.21             136 561 996--142 584 570       6 022 574                            46                                 19                                                             
  4q34.3-q35.1              182 303 764--182 934 067        630 303                             49                                 1                                                             *NCRNA00290*
  6q26                      161 740 093--161 828 041        87 948                              44                                 1          *PARK2*                                             
  8p23.3-p23.1              1 190 650--6 260 759           5 070 109                          **56**                               9          *MCPH1*                                             
  8p21.2-p21.1              26 260 243--28 304 348         2 044 105                            47                                 21                                                             
  **9p24.3**                0--1 631 746                   1 631 746                            51                                 11                                                             
  9p24.1                    8 056 737--8 434 111            377 374                             50                                 1          *PTPRD*                                             
  9p23-p22.3                12 386 932--14 108 018         1 721 086                            51                                 5          ***NFIB***                                         *TYRP1 C9orf150 MPDZ FLJ41200*
  9p22.3                    14 622 555--16 229 616         1 607 061                            35                                 8                                                              
  9p22.3-p21.3              16 479 078--20 933 035         4 453 957                            51                                 17         ***MLLT3***                                         
  **9p21.3**                21 969 065--22 051 061          81 996                              54                                 3          ***CDKN2A CDKN2B***                                *CDKN2BAS*
  9q21.33                   88 865 092--89 129 765          264 673                             44                                 2                                                             *LOC494127 C9orf170*
  9q22.32                   96 898 992--97 116 235          217 243                             43                                 1          ***FANCC***                                         
  9q22.33-q31.1             100 644 626--101 678 237       1 033 611                            43                                 3          ***NR4A3***                                        *GALNT12 COL15A1 TGFBR1 ALG2 SEC61B*
  9q33.1                    117 953 363--118 381 663        428 300                             46                                 3                                                             *PAPPA LOC100128505 ASTN2*
  9q33.2                    123 060 025--123 208 621        148 596                             46                                 2                                                             *GSN STOM*
  9q33.3                    128 975 869--129 006 542        30 673                              35                                 1                                                             *RALGPS1*
  9q34.13-q34.2             133 483  430--135 001 392      1 517 962                            51                                 17         ***TSC1***                                          
  9q34.2                    135 339 532--135 424 778        85 246                              53                                 2                                                             *TMEM8C ADAMTSL2*
  11p15.5-p15.4             826 091--2 876 898             2 050 807                            41                                 44                                                             
  13q12.13                  25 719 218--25 817 850          98 632                              44                                 1                                                             *CDK8*
  16p13.3                   3 759 661--3 782 779            23 118                              35                                 1          ***CREBBP***                                        
  16q21                     62 541 693--64 974 691         2 432 998                            40                                 3          ***CDH11***                                        *LOC283867 CDH5*
  16q22.3-q23.1             73 046 913--74 862 172         1 815 259                            40                                 20                                                             
  17p13.3                   1 431 769--1 639 791            208 022                           **57**                               11                                                             
  17p11.2                   19 082 703--20 046 930          964 227                           **63**                               15                                                             
  **17q11.2**-**q12**       26 420 214--29 077 825         2 657 611                            54                                 4          ***NF1***                                          *TMEM98 SPACA3 ACCN1*
  18q21.2                   48 644 312--51 715 504         3 071 192                            40                                 9                                                              
  18q21.32-q21.33           55 721 386--57 214 344         1 492 958                            40                                 2                                                             *PMAIP1 MC4R*
  18q23                     75 912 794--76 117 153          204 359                             44                                 3                                                             *ADNP2 LOC100130522 PARD6G*
  22q12.3                   30 817 999--32 856 500         2 038 501                            43                                 12                                                             
  **22q12.3**               32 856 500--34 737 030         1 880 530                            53                                 10                                                             
  22q12.3                   34 737 030--35 049 039          312 009                             43                                 6          ***MYH9***                                         *RBFOX2 APOL3 APOL4 APOL2 APOL1*
  **22q13.1**               37 668 125--37 724 138          56 013                              53                                 2                                                             *APOBEC3A APOBEC3B*
  22q13.1                   43 530 191--46 673 931         3 143 740                            53                                 32                                                             
  **22q13.31**-**q13.33**   46 673 931--49 472,215         2 798 284                            54                                 40                                                             
  Xq11.1-q12                62 673 834--65 512 219         2 838 385                            35                                 14                                                             
  Xq12                      65 512 219--66 014 702          502 483                             46                                 1          *EDA2R*                                             
  Xq12-q13.1                66 014 702--68 066 344         2 051 642                            35                                 5          *AR*                                               *OPHN1 YIPF6 STARD8 EFNB1*
  Xq27.3                    144 141 243--146 657 619       2 516 376                            41                                 21                                                             

Gained and lost regions listed as shared across tumour subtypes if present among the top 60 most frequently altered regions (minimum frequency=25%) in at least three tumour subtypes (BRCA1, B1; BRCA2, B2; BRCAX, BX; Sporadic, S). In bold regions found to be recurrent in all four tumour groups.

Global frequency of the alteration in whole tumour set; frequencies greater or equal to 55% highlighted in bold.

Genes of interest selected from Cancer Census (in bold) or based on their function and previously published data.

Rest of the genes in the defined region listed if less than seven.

###### Distribution of most frequent amplifications and homozygous deletions across tumour subtypes

                                                                                **No. of samples with alteration**                                                 
  -------------------------- -------------------------- ----------- ---------- ------------------------------------ --- --- --- --- ---- ------------------------- -----------------------------------------------------------
  **Amplifications**                                                                                                                                               
  3q26.2                     170 112 026--170 346 939     234 913      5.9                      4                    1          3    1          ***MECOM***        *MECOM*
  3q26.32-q26.33             179 526 769--181 046 005    1 519 236     5.9                      4                            1  3    12        ***PIK3CA***         
  7q36.3                     155 939 892--158 642 803    2 702 911     5.9                      4                    2       2       16                             
  **8q21.2**-**q21.3**       85 047 239--87 355 110      2 307 871     5.9                      4                    2       1  1    15                             
  **8q21.3**                 92 323 386--92 443 508       120 122      7.4                      5                    3       1  1    1                             *SLC26A7*
  8q22.1                     94918806--95 029 680         110874       5.9                      4                    3       1       1                             *PDP1*
  **8q22.1**                 96 742 090--97 658 770       91 668       7.4                      5                    3       1  1    6                             *LOC100500773 GDF6 UQCRB*
                                                                                                                                                                   *MTERFD1 PTDSS1 SDC2*
  8q22.1                     98 814 783--98 930 489       115 706    **8.8**                    6                    6               1           *LAPTM4B*         *LAPTM4B*
  **8q22.3**                 101 926 982--102 101 553     174 571    **11.8**                   8                    5       1  2    1            *YWHAZ*          *YWHAZ*
  8q23.1                     107 121 208--108 087 190     965 982    **10.3**                   7                    4       3       2                             *OXR1 ABRA*
  8q23.1-q23.2               110 438 342--111 177 707     739 365    **11.8**                   8                    4       4       4                             *PKHD1L1 EBAG9 SYBU KCNV1*
  8q24.11                    118 543 986--118 626 272     82 286     **14.7**                   10                   3   1   6       1                             *MED30*
  8q24.13                    122 701 184--123 202 812     501 628    **13.2**                   9                    3   1   5       2                             *HAS2 HAS2AS*
  8q24.21                    128 537 094--128 997 964     460 870    **19.1**                   13                   5   2   6       2           ***MYC***         *MYC PVT1*
  8q24.23-q24.3              139 929 002--142 315 091    2 386 089   **22.1**                   15                   7   2   6       8           *TRAPPC9*         *COL22A1 KCNK9 TRAPPC9 CHRAC1 EIF2C2 PTK2 DENND3 SLC45A4*
  **11q13.1**                64 958 966--65 036 226       77 260     **11.8**                   8                    3       2  3    2           *MALAT1*          *MIR612 MALAT1*
  17q12-q21.1                35 083 091--35 415 740       332 649      5.9                      4                            2  2    11         ***ERBB2***         
  19p13.2                    8 939 055--10 745 326       1 806 271     5.9                      4                            2  2    33           *MUC16*           
  20q13.2                    51 530 308--52 731 992      1 201 684     5.9                      4                            2  2    7                             *TSHZ2 ZNF217 SUMO1P1 BCAS1 CYP24A1 PFDN4 DOK5*
  **20q13.31**               54 436 225--55 409 396       973 171      5.9                      4                    1       2  1    12                             
  **Homozygous deletions**                                                                                                                                         
  1p36.32                    4 132 552--4 616 506         483 954      4.4                      3                    3               2            *AJAP1*          *LOC284661 AJAP1*
  **3p14.2**                 60 530 653--60 943 377       412 724      4.4                      3                        1   1  1    1          ***FHIT***         *FHIT*
  **5q15**                   95 249 110--95 428 565       179 455      4.4                      3                    1       1  1    1                             *ELL2*
  8p23.3                     0--206 224                   206 224    **7.4**                    5                    4   1           3                             *OR4F21 RPL23AP53 ZNF596*
  **8p23.2**-**p23.1**       6 177 456--6 455 595         278 139    **7.4**                    5                    3   1      1    2            *MCPH1*          *MCPH1 ANGPT2*
  8p22-p21.3                 17 000 420--19 725 139      2 724 719   **5.9**                    4                    3          1    17      ***PCM1** MTUS1*       
  8p21.3-p21.2               22 096 663--26 106 924      4 010 261   **7.4**                    5                    4          1    37     *DOCK5 CDCA2 EBF2*      
  8p21.1-p12                 28 636 935--33 247 321      4 610 386     4.4                      3                    2          1    21   *WRN DUSP4 HMBOX1 NRG1*   
  **13q14.2**                47 841 552--47 847 231        5679      **8.8**                    6                    2       3  1    1           ***RB1***         *RB1*
  16q23.3                    80 791 319--82 209 820      1 418 501     4.4                      3                    3               2            *CDH13*          *CDH13 MIR3182*
  **17q11.2**                26 516 613--26 548 438       31 825     **8.8**                    6                    1   1   2  2    1           ***NF1***         *NF1*
  **19q13.43**               61 855 409--62 293 274       437 865      4.4                      3                    1       1  1    6          *PEG3 ZIM2*        *LOC147670 ZNF835 ZIM2*
                                                                                                                                                                   *PEG3AS PEG3 MIMT1*
  22q13.31-q13.33            46 034 061--48 551 789      2 517 728     4.4                      3                    2       1       4                             *FLJ46257 MIR3201 FAM19A5 C22orf34*
  **Xp22.11**-**p21.3**      24 744 413--25 039 949       295 536      4.4                      3                    1       1  1    2                             *POLA1 ARX*
  **Xp21.1**                 31 763 941--33 579 700      1 815 759   **5.9**                    4                    1       1  2    1                             *DMD*
  **Xp11.4**                 38 519 008--39 470 641       951 633      4.4                      3                    1       1  1    1                             *MID1IP1*
  **Xp11.3**                 43 295 963--43 705 583       409 620    **5.9**                    4                    1       2  1    3                             *MAOA MAOB NDP*
  Xp11.3                     44 198 148--44 786 777       588 629      4.4                      3                    1       2       3          ***KDM6A***        *FUNDC1 DUSP21 KDM6A*
  Xp11.3-p11.23              46 905 791--48 631 317      1 725 526     4.4                      3                    2       1       45    ***SSX4 WAS GATA1***     
  **Xp11.23**-**p11.22**     49 634 473--49 949 828       315 355      4.4                      3                    1       1  1    10                             

Amplifications and homozygous deletions with frequencies greater than 5% (⩾4 samples) and 4% (⩾3 samples), respectively. Cytobands in bold indicate regions found in sporadic and at least two of the familial subtypes. BRCA1, B1; BRCA2, B2; BRCAX, BX; Sporadic, S.

Global frequency of the alteration in whole tumour set; frequencies \>5% are highlighted in bold.

Genes of interest selected from Cancer Census (in bold) or based on their function and previously published data.

Rest of genes in the defined region (a maximum of six genes per region is shown).
